Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

Source: Key Decisions in HIV Care
Listen as William R. Short, MD, MPH, AAHIVS, discusses the data to help you determine when switching to 2-drug single-tablet regimens may be warranted.
William R. Short, MD, MPH, AAHIVS
Released: November 10, 2021

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.

Listen as he gives his perspectives on:

  • Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
  • The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
  • Real-world experience with switching to DTG/RPV from the OPERA study
  • The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
  • The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen

Information on this Educational Activity

Faculty

William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS, has disclosed that he has received fees for non-CME/CE services from Janssen and consulting fees from ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022
Introductory Case
Question and Answer Session

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Paul E. Sax, MD Released: May 6, 2022

Expert selections of important HIV data from CROI 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Daniel R. Kuritzkes, MD Released: May 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings